Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jincao Zhike Oral Solution is a Traditional Chinese Medicine (TCM) formulation developed by Beijing Langzhen Pharmaceutical Technology Co., Ltd. for the treatment of pediatric acute bronchitis. It is specifically indicated for patients presenting with the 'phlegm-heat obstructing lung' pattern, a TCM diagnosis characterized by symptoms such as cough, yellow phlegm, and fever. The solution is designed to clear pulmonary heat, resolve phlegm, and alleviate respiratory distress. As of 2022, the drug is undergoing Phase 3 clinical evaluation in China (CTR20222606) to establish its safety and efficacy in children, comparing standard therapeutic doses against a very low-dose control group.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jincao Zhike Oral Solution.